Biologic · Primary entity is a cell therapy with no ChEMBL entity, so resolved=false. The co-administered small molecule is aspirin = CHEMBL25 ASPIRIN (max_phase 4, first approval 1950, ATC B01AC06 / N02BA01 / A01AD05, not withdrawn), recorded here for reference only; the chembl_id field is deliberately left empty because the cells, not the aspirin, are the therapy of interest. EXACT COMBINATION MATCH: both recorded trials give allogeneic human umbilical cord MSC together with aspirin, matching the with-or-without-aspirin design, though the indication is acute or convalescent cerebral infarction rather than trauma. Both are SUSPENDED with start dates listed in the future (2026-12-31), so neither has generated results.
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Cerebral Infarction
Enrolment: 40 · Results not recorded
Cerebral Infarction
Enrolment: 40 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Transient middle cerebral artery occlusion (focal cerebral ischaemia)
Aspirin and human umbilical cord matrix-derived mesenchymal cells each significantly improved learning and memory recovery and reduced the ischaemic area compared with untreated ischaemic rats; coadministration gave no additional benefit over either treatment alone.
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.
